Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$4.77 +1.7%	$4.70	$3.61 ▼ $11.09	$56.24M	1.52	335,480 shs	61,454 shs
HOWL Werewolf Therapeutics	$1.32 -2.2%	$1.23	$0.60 ▼ $4.18	$59.23M	0.63	367,583 shs	215,813 shs
ME 23andMe	$0.50 -35.3%	$0.50	$0.53 ▼ $9.57	$13.36M	1.19	1.57 million shs	29.28 million shs
UNCY Unicycive Therapeutics	$4.63 +5.0%	$5.34	$2.75 ▼ $11.00	$58.53M	1.88	358,267 shs	530,312 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	+7.08%	-2.49%	+1.08%	+3.08%	-47.60%
HOWL Werewolf Therapeutics	+12.50%	+13.45%	+4.65%	+21.62%	-34.15%
ME 23andMe	0.00%	0.00%	0.00%	0.00%	-92.80%
UNCY Unicycive Therapeutics	+3.76%	+6.27%	-9.63%	-19.91%	+86.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DTIL Precision BioSciences	4.2517 of 5 stars	3.5	3.0	0.0	4.6	2.2	1.7	0.6
HOWL Werewolf Therapeutics	4.0489 of 5 stars	3.5	5.0	0.0	0.0	2.7	5.0	0.6
ME 23andMe	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	2.5986 of 5 stars	3.7	2.0	0.0	0.0	2.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DTIL Precision BioSciences	3.00	Buy	$47.00	898.94% Upside
HOWL Werewolf Therapeutics	3.00	Buy	$8.33	524.22% Upside
ME 23andMe	0.00	N/A	N/A	N/A
UNCY Unicycive Therapeutics	3.33	Buy	$60.00	1,204.63% Upside

Current Analyst Ratings Breakdown

Latest ME, HOWL, UNCY, and DTIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$90.00
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DTIL Precision BioSciences	$68.70M	0.81	N/A	N/A	$2.89 per share	1.63
HOWL Werewolf Therapeutics	$1.14M	52.41	N/A	N/A	$1.65 per share	0.81
ME 23andMe	$208.78M	0.06	$0.54 per share	0.93	$2.34 per share	0.21
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DTIL Precision BioSciences	$7.17M	-$8.81	N/A	N/A	N/A	-6,205.79%	-176.47%	-69.05%	N/A
HOWL Werewolf Therapeutics	-$70.51M	-$1.67	N/A	N/A	N/A	N/A	-89.37%	-54.87%	8/14/2025 (Estimated)
ME 23andMe	-$666.70M	-$15.45	N/A	∞	N/A	-183.39%	-170.07%	-62.13%	N/A
UNCY Unicycive Therapeutics	-$36.73M	-$5.10	N/A	N/A	N/A	N/A	-277.30%	-61.53%	N/A

Latest ME, HOWL, UNCY, and DTIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	HOWL Werewolf Therapeutics	-$0.50	-$0.40	+$0.10	-$0.40	N/A	N/A
8/13/2025	Q2 2025	UNCY Unicycive Therapeutics	-$0.70	-$0.52	+$0.18	-$0.52	N/A	N/A
8/7/2025	Q2 2025	DTIL Precision BioSciences	-$0.09	-$2.13	-$2.04	-$2.13	$6.27 million	$0.02 million
5/15/2025	Q1 2025	DTIL Precision BioSciences	-$0.43	-$2.21	-$1.78	-$2.21	$5.00 million	$0.03 million
5/14/2025	Q1 2025	UNCY Unicycive Therapeutics	-$1.40	-$0.50	+$0.90	-$0.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
ME 23andMe	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DTIL Precision BioSciences	0.66	5.18	5.18
HOWL Werewolf Therapeutics	0.46	8.09	8.09
ME 23andMe	N/A	1.05	0.91
UNCY Unicycive Therapeutics	N/A	1.64	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DTIL Precision BioSciences	37.99%
HOWL Werewolf Therapeutics	64.84%
ME 23andMe	36.10%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
DTIL Precision BioSciences	4.50%
HOWL Werewolf Therapeutics	23.60%
ME 23andMe	26.32%
UNCY Unicycive Therapeutics	10.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DTIL Precision BioSciences	200	11.79 million	11.26 million	No Data
HOWL Werewolf Therapeutics	40	44.87 million	34.28 million	Optionable
ME 23andMe	770	26.83 million	19.77 million	Not Optionable
UNCY Unicycive Therapeutics	9	12.64 million	11.29 million	Not Optionable

ME, HOWL, UNCY, and DTIL Headlines

Recent News About These Companies

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

2 hours ago | gurufocus.com

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

2 hours ago | globenewswire.com

Unicycive Therapeutics requests Type A meeting with FDA to discuss CRL

4 hours ago | msn.com

Unicycive Therapeutics expects cash to fund operations into 2H of 2026

4 hours ago | msn.com

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

August 14 at 7:00 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 13 at 12:33 PM | globenewswire.com

Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Wednesday

August 12 at 8:43 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 11 at 10:00 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 9, 2025 | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Holdings Lifted by Vivo Capital LLC

August 9, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 6, 2025 | prnewswire.com

Short Interest in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Grows By 1,211.2%

August 4, 2025 | americanbankingnews.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Up 1,211.2% in July

August 3, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 31, 2025 | prnewswire.com

Unicycive Therapeutics Inc Ordinary Shares UNCY - Morningstar

July 30, 2025 | morningstar.comM

Unicycive Therapeutics (NASDAQ:UNCY) Trading Down 6.2% - Here's What Happened

July 30, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 28, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 27, 2025 | prnewswire.com

Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology

July 24, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 23, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 22, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ME, HOWL, UNCY, and DTIL Company Descriptions

Precision BioSciences NASDAQ:DTIL

$4.77 +0.08 (+1.71%)

Closing price 04:00 PM Eastern

Extended Trading

$4.74 -0.03 (-0.63%)

As of 04:38 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Werewolf Therapeutics NASDAQ:HOWL

$1.32 -0.03 (-2.22%)

Closing price 04:00 PM Eastern

Extended Trading

$1.32 +0.00 (+0.38%)

As of 04:10 PM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

23andMe NASDAQ:ME

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

Unicycive Therapeutics NASDAQ:UNCY

$4.63 +0.22 (+4.99%)

Closing price 04:00 PM Eastern

Extended Trading

$4.57 -0.06 (-1.40%)

As of 05:14 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time